NewAmsterdam Pharma Company

NAMSPre-clinical

NewAmsterdam Pharma is dedicated to transforming the treatment of cardiometabolic diseases through innovative oral therapies. The company's primary focus is on advancing obicetrapib, a next-generation CETP inhibitor, through late-stage clinical trials for patients with high cardiovascular risk. With a strong leadership team experienced in drug development and commercialization, NewAmsterdam is positioned to potentially bring a new class of lipid-modifying therapy to market. The company leverages strategic partnerships and public market financing to support its ambitious clinical development programs.

Market Cap

$3.3B

Employees

50-100

Focus

Biotech

NAMS · Stock Price

USD 28.94+19.11 (+194.40%)

Historical price data

AI Company Overview

Technology Platform

Selective cholesterol ester transfer protein (CETP) inhibition platform focused on developing oral therapies with optimized pharmacological properties for lipid metabolism modulation.

Funding History

Total raised: $371M

IPO$175MUndisclosedOct 7, 2022

Series A$196MForbionMay 15, 2021

Opportunities

Obicetrapib's oral administration provides a significant advantage over injectable competitors in the dyslipidemia market.

Successful demonstration of cardiovascular outcomes benefit in the PREVAIL trial could support blockbuster potential and broad patient access.

Combination therapy approaches with existing lipid-lowering agents create additional market expansion opportunities.

Risk Factors

The CETP inhibitor class has a history of clinical failures, creating skepticism among clinicians and investors.

Phase 3 trials may not confirm promising Phase 2 data, and the cardiovascular outcomes trial represents a high-cost, high-risk endeavor.

Commercial success depends on demonstrating meaningful clinical benefits beyond LDL-C reduction alone.

Competitive Landscape

NewAmsterdam faces competition from established PCSK9 inhibitors (Amgen, Regeneron/Sanofi), novel siRNA therapies (Novartis), and other oral agents (Esperion). Differentiation centers on obicetrapib's oral administration, favorable safety profile, and potential complementary mechanism when combined with existing therapies.

Publications